MRUS Stock Overview
Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Merus N.V. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$40.47 |
| 52 Week High | US$52.04 |
| 52 Week Low | US$18.21 |
| Beta | 1.11 |
| 1 Month Change | -10.09% |
| 3 Month Change | 15.66% |
| 1 Year Change | 94.94% |
| 3 Year Change | 70.40% |
| 5 Year Change | 148.43% |
| Change since IPO | 303.09% |
Recent News & Updates
Recent updates
Merus: Positive Zenocutuzumab Data In 2024 Could Provide BLA Advancement
Mar 01Merus N.V.'s (NASDAQ:MRUS) Shares Climb 30% But Its Business Is Yet to Catch Up
Feb 01
Merus Stock: Rally Seems Overdone
Jan 23Are Investors Undervaluing Merus N.V. (NASDAQ:MRUS) By 45%?
Jan 14Risks To Shareholder Returns Are Elevated At These Prices For Merus N.V. (NASDAQ:MRUS)
Dec 18We Think Merus (NASDAQ:MRUS) Needs To Drive Business Growth Carefully
Sep 19Merus N.V.'s (NASDAQ:MRUS) Business Is Yet to Catch Up With Its Share Price
Jun 20Is Merus (NASDAQ:MRUS) In A Good Position To Invest In Growth?
May 24Merus N.V. (NASDAQ:MRUS) Shares Could Be 26% Below Their Intrinsic Value Estimate
Feb 08Merus GAAP EPS of -$0.13 beats by $0.49, revenue of $12.68M beats by $2.23M
Aug 08Merus N.V. initiated with Buy at Stifel based on three bispecific antibodies
Aug 02Merus: Precision Oncology Pioneer Continues To Execute In The Clinic
Jun 30Need To Know: Analysts Are Much More Bullish On Merus N.V. (NASDAQ:MRUS)
May 14Merus (NASDAQ:MRUS) Is In A Strong Position To Grow Its Business
Apr 25New Forecasts: Here's What Analysts Think The Future Holds For Merus N.V. (NASDAQ:MRUS)
Mar 03We're Not Worried About Merus' (NASDAQ:MRUS) Cash Burn
Nov 25News Flash: Analysts Just Made A Sizeable Upgrade To Their Merus N.V. (NASDAQ:MRUS) Forecasts
Aug 08Calculating The Intrinsic Value Of Merus N.V. (NASDAQ:MRUS)
Jul 28We're Not Very Worried About Merus' (NASDAQ:MRUS) Cash Burn Rate
Jul 02Merus posts positive efficacy data from early-stage zenocutuzumab cancer study
Jun 04Merus EPS misses by $0.10, misses on revenue
May 06Is Merus N.V. (NASDAQ:MRUS) Popular Amongst Institutions?
Mar 08Shareholder Returns
| MRUS | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -6.1% | -4.7% | -3.7% |
| 1Y | 94.9% | -2.7% | 20.2% |
Return vs Industry: MRUS exceeded the US Biotechs industry which returned -2% over the past year.
Return vs Market: MRUS exceeded the US Market which returned 20.5% over the past year.
Price Volatility
| MRUS volatility | |
|---|---|
| MRUS Average Weekly Movement | 6.0% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: MRUS's share price has been volatile over the past 3 months.
Volatility Over Time: MRUS's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | 201 | Bill Lundberg | www.merus.nl |
Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma.
Merus N.V. Fundamentals Summary
| MRUS fundamental statistics | |
|---|---|
| Market cap | US$2.38b |
| Earnings (TTM) | -US$154.94m |
| Revenue (TTM) | US$43.95m |
54.0x
P/S Ratio-15.3x
P/E RatioIs MRUS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MRUS income statement (TTM) | |
|---|---|
| Revenue | US$43.95m |
| Cost of Revenue | US$140.66m |
| Gross Profit | -US$96.71m |
| Other Expenses | US$58.23m |
| Earnings | -US$154.94m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.64 |
| Gross Margin | -220.06% |
| Net Profit Margin | -352.56% |
| Debt/Equity Ratio | 0% |
How did MRUS perform over the long term?
See historical performance and comparison